CN201161003Y - Ocular surface biomembrane - Google Patents
Ocular surface biomembrane Download PDFInfo
- Publication number
- CN201161003Y CN201161003Y CNU2007200596890U CN200720059689U CN201161003Y CN 201161003 Y CN201161003 Y CN 201161003Y CN U2007200596890 U CNU2007200596890 U CN U2007200596890U CN 200720059689 U CN200720059689 U CN 200720059689U CN 201161003 Y CN201161003 Y CN 201161003Y
- Authority
- CN
- China
- Prior art keywords
- biological film
- curved surface
- eyeball
- ocular surface
- film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241001465754 Metazoa Species 0.000 claims abstract description 19
- 210000005252 bulbus oculi Anatomy 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000001050 lubricating effect Effects 0.000 claims abstract description 5
- 239000012528 membrane Substances 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 11
- 102000036639 antigens Human genes 0.000 abstract description 11
- 108091007433 antigens Proteins 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 10
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 8
- 230000001954 sterilising effect Effects 0.000 abstract description 7
- 239000004593 Epoxy Substances 0.000 abstract description 5
- 230000035876 healing Effects 0.000 abstract description 4
- 210000003516 pericardium Anatomy 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000009423 ventilation Methods 0.000 abstract 2
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000005238 degreasing Methods 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 230000005251 gamma ray Effects 0.000 abstract 1
- 210000000569 greater omentum Anatomy 0.000 abstract 1
- 210000004379 membrane Anatomy 0.000 description 13
- 150000002118 epoxides Chemical class 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 210000001508 eye Anatomy 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 7
- -1 benzyl fluosulfonic acid Chemical compound 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 210000001691 amnion Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000000474 nursing effect Effects 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The utility model provides an ocular surface biological film which is an animal film that is prepared by using pericardium, goldbeater's skin, and caul fat as raw material and through the processes of degreasing, cell free, multiaspect antigen elimination, epoxy hardening, curve generating, surface finish, cobalt-60 gamma-ray irradiation disinfection, etc. as well as is provided with a curved surface which is similar with the eyeball. A medicine slow-released layer, a ventilation millipore and a lubricating layer are arranged in a biological film curved surface. The ocular surface biological film is provided with the curved surface which is same with the eyeball and can cling to the eyeball, has no antigenicity and better histocompatibility, can be concerned with the healing process of the ocular surface wound, and is beneficial for the healing of the wound. The ocular surface biological film has better ventilation property and sterilization filtration, can protect and heal better the ocular surface, and has better strength. The biological film can paste and sew, so the use is convenient.
Description
Technical field
This utility model relates to a kind of ophthalmic nursing and treatment eye table dressing of being used for, and belongs to three class medical apparatus and instruments, is specially a kind of eye-surface biological film.
Background technology
The treatment of eye's cornea and conjunctival damage, inflammation and nursing, the nursing after the corneal transplantation all need be used the dressing of eye table.Traditional eye table dressing is general antiseptic gauze, can not contact closely with ocular surface, can only play simple covering effect.In recent years, it is tissue film's work eye table dressing of raw material with people's placenta amnion that scientist has developed a kind of, can directly be affixed on ocular surface, has better effect to promoting damage and inflammation healing.The used fixing means of placenta amnion is to handle with traditional glutaraldehyde, and glutaraldehyde fixedly has residual toxicity, directly can influence healing effect.And only use the gamma-radiation irradiation deactivation of 10～15KGy, do not have the custom-designed antigen that removes again and handle, also strict inadequately to killing of the virus that may exist, worrying virus disseminating.In addition, people's placenta amnion source is very limited, can not apply widely.
The utility model content
The purpose of this utility model is the deficiency that exists at the above table dressing, provides a kind of and has the curved surface that adapts with eyeball and form close eye-surface biological film with people's cornea, conjunctiva.
The technical solution of the utility model is: a kind of eye-surface biological film, and for having the animal membrane to the similar curved surface of eyeball.
Be provided with the medicament slow release layer in the described biomembrane curved surface.
Have in the described biomembrane curved surface by the ventilative micropore of biomembrane natural micropore through suitably enlarging.
In the described biomembrane curved surface lubricating layer is set.
This utility model is achieved in that a kind of eye-surface biological film, is made into by following steps:
(1) the animal membrane material is got in selection;
(2) pretreatment: prune and remove excess tissue, fiber or fine hair etc.;
(3) ungrease treatment: with organic solvent extraction fatty impurity wherein;
(4) take off cell: under the protectant effect of collagen, decompose cell with surfactant or protease;
(5) the multi-faceted antigen that removes is handled: combine with being in active group certain special position, that cause immune rejection in some active nucleopilic reagents and the collagen protein, with its sealing, and use strong hydrogen bonding and form agent destruction and cause antigenic special conformation;
(6) fixing: as with epoxide the collagen in the film material to be carried out crosslinked fixing, to improve its stability;
(7) curved surface forming: making film material forming with the sphere mould is corresponding curved surface with eyeball;
(8) finishing;
(9) packing;
(10) virus of going out: gamma-radiation irradiation sterilization;
(11) finished product.
The animal membrane material of being got comprises pericardium, goldbeater's skin, fat nethike embrane, the placenta amnion of animals such as pig, cattle, sheep;
Described pretreatment is to prune to remove excess tissue, fiber or fine hair etc.;
Described ungrease treatment is that organic solvent can be acetate esters, chloroform, carbon tetrachloride, ether, acetone, dehydrated alcohol with organic solvent extraction fatty impurity wherein;
Described take off cell be with the surfactant elution method and in the presence of collagen is protectant enzymatic isolation method, both use separately or both should be used for realizing simultaneously; Surfactant is ethylenediaminetetraacetic acid, benzyl fluosulfonic acid, Triton X-100 (Tritonx100), Tris (Tris), and the used enzyme of enzymatic isolation method is a protease, can be trypsin and pepsin etc.
The described multi-faceted antigen that removes is handled, be in certain special position with in some active nucleopilic reagents and the collagen protein, cause that the active group of immune rejection combines, with its sealing, and application strong hydrogen bonding formation agent destruction causes antigenic special conformation; Active group described here mainly is-OH
*,-NH
2 *,-SH
*Deng; Applicable active nucleopilic reagent has anhydride, amide, epoxide etc.; Applicable strong hydrogen bonding forms agent guanidine compound.
The fixing processing of described epoxy is meant with epoxide carries out crosslinked fixing to the collagen protein in the film material, to improve its stability.Used epoxide can be the carbochain epoxide
R=C wherein
nH
2n+1-,
N=0,1～10, also can be carbon oxygen chain epoxide
R=C wherein
nH
2n+1-,
R '=H, CH
3-(C
2H
5)
n-, n=0,1,2 ... n, x=0,1,2 ... x.Compare with traditional glutaraldehyde fixation, the fixed cross-bond of epoxy is stable, can not discharge deleterious aldehydes, non-residual toxicity during degraded.
Described molding is that to make film material forming with the sphere mould be corresponding curved surface with eyeball.
In addition, this product also can increase the finishing of slow release treatment medicine according to the treatment needs after molding, and method is with the slow release lapping medicine to be wrapping on the product; Or the modification of increase lubricity, method is that hyaluronic acid is introduced this biomembrane; Maybe can increase the finishing of breathability, method is to make with the multi tension typing method that micropore suitably enlarges in the film.
At last product is packed with the double-layer plastic bag, the reuse sufficient dosage (as＞30KGy) gamma-radiation irradiation sterilization, to kill the exogenous or animal derived virus and the pathogenic bacteria that may exist.
It is raw material with the animal membrane material that this utility model provides a kind of, replace glutaraldehyde to fix with epoxide, use the multi-faceted antigen technology of removing and remove antigen, carry out effective deactivation with the radiating classical sterilization of 25KGy gamma-radiation to the potential virus of possibility, again the sphere biomembrane that makes through molding with certain curvature radius.The utlity model has the curved surface similar, can be close to eyeball to eyeball; No antigen, histocompatibility is good, can participate in the agglutination of eye table wound, helps wound healing; Have air permeability and good and antibacterial filtering simultaneously, can play the good protection therapeutical effect the eye table; Have better intensity, can paste and can stitch, easy to use; Finishing by medicament slow release in addition, but also can be made into the therapeutic type eye-surface biological film of slow release anti-infectives.
Description of drawings
Fig. 1 is the structural representation of a kind of eye-surface biological film of this utility model;
Fig. 2 is the structural representation of a kind of eye-surface biological film band of this utility model medicament slow release layer.
The specific embodiment
Below in conjunction with the specific embodiment this utility model is described in detail.
A kind of eye-surface biological film as shown in Figure 1, is the animal membrane 1 that has to the similar curved surface of eyeball, can directly be affixed on ocular surface, is used for the treatment and the nursing of eye's cornea and conjunctival damage, inflammation, and the nursing after the corneal transplantation.According to the needs of treatment, be provided with the medicament slow release layer 2 of slow release treatment medicine in the animal membrane curved surface by finishing, as shown in Figure 2.Medicament slow release layer 2 is for to be wrapping to medicine on the animal membrane with the slow release lapping.In addition, animal membrane can be introduced lubricating layer, and to increase lubricity, lubricating layer can be a hyaluronic acid; Or the micropore of expansion is set by the multi tension typing method, to increase breathability.
It has the curved surface similar to eyeball a kind of eye-surface biological film of the present utility model, can be close to eyeball, its no antigen, and histocompatibility is good, can participate in the agglutination of eye table wound, helps wound healing; Have air permeability and good and antibacterial filtering, can play the good protection therapeutical effect the eye table; Have better intensity, can paste and can stitch, easy to use.Finishing by medicament slow release in addition, but also can be made into the therapeutic type eye-surface biological film of slow release anti-infectives.
A kind of eye-surface biological film of the present utility model is made into by following steps:
(1) get the animal membrane material: the animal membrane material that can choose comprises pericardium, goldbeater's skin, fat nethike embrane, placenta amnion of animals such as pig, cattle, sheep etc.;
(2) pretreatment: prune and remove impurity such as excess tissue, fiber or fine hair, with convenient follow-up processing;
(3) ungrease treatment: with organic solvent extraction fatty impurity wherein, the organic solvent that extracts fat can be dehydrated alcohol, ethyl acetate, acetone, chloroform etc.;
(4) take off cell: be with the surfactant elution method and in the presence of collagen is protectant enzymatic isolation method, both use separately or both should be used for realizing simultaneously; Surfactant is ethylenediaminetetraacetic acid, benzyl fluosulfonic acid, Triton X-100 (Tritonx100), Tris (Tris), and the used enzyme of enzymatic isolation method is a protease, can be trypsin and pepsin etc.
(5) the multi-faceted antigen that removes is handled: combine with being in active group certain special position, that cause immune rejection in some active nucleopilic reagents and the collagen protein, with its sealing, and use strong hydrogen bonding and form agent and destroy and cause antigenic special conformation, active group described here mainly is-OH
*,-NH
2 *,-SH
*Deng; Nucleopilic reagent can be anhydride, amide, epoxide etc.; It can be guanidine compound that strong hydrogen bonding forms agent.
(6) fixing: as with the carbochain epoxide collagen protein in the film material to be carried out crosslinked fixing, to improve its stability; Used epoxide can be the carbochain epoxide
R=C wherein
nH
2n+1-,
N=0,1～10, also can be carbon oxygen chain epoxide
R=C wherein
nH
2n+1-,
R '=H, CH
3-(C
2H
5)
n-, n=0,1,2 ... n, x=0,1,2 ... x.Compare with traditional glutaraldehyde fixation, the fixed cross-bond of epoxy is stable, can not discharge deleterious aldehydes, non-residual toxicity during degraded.
(7) curved surface forming: making film material forming with the sphere mould is corresponding curved surface with eyeball;
(8) finishing: can be according to the treatment needs, the animal membrane after molding increases the finishing of slow release treatment medicine, can be with the slow release lapping medicine to be wrapping on the animal membrane; Also can increase the modification of lubricity, as hyaluronic acid is introduced in the film body; Maybe can increase the finishing of breathability, make by the multi tension typing method that micropore suitably enlarges in the film.
(9) packing: product is packed with the double-layer plastic bag;
(10) virus of going out: with the gamma-radiation irradiation sterilization of sufficient dosage, to kill the exogenous or animal derived virus and the pathogenic bacteria that may exist, the dosage of used gamma-radiation is no less than 30KGy;
(11) finished product.
Get fresh pig pericardium or pig small intestine film, put into preservative specially and soak sterilization fresh, carefully remove the impurity on the striping, drain away the water, put into organic solvents such as dehydrated alcohol, ethyl acetate, acetone, chloroform, extracting is more than 6 hours, to remove fatty impurity wherein.Reuse protease hydrolyzed method removes wherein cell, and protease can be used trypsin, pepsin or both mixing.Hydrolysis temperature is 18-25 ℃, and enzymolysis time is more than 2 hours.Reuse is epoxy crosslinked fixing, and used epoxide is
Here R=C
nH
2n+1-or
N=0,1,2, n cleans, and drains, and reuse butyryl oxide. or butyl chloride seal active antigen group, and active here antigen group mainly is to contain-OH-NH
2, the specific activity group of-SH is to remove its antigenicity.Clean, the spherical film tool of reuse is pressed into curved surface and drawing and setting and forms as shown in Figure 1 the animal membrane 1 to the similar curved surface of eyeball of having.Packing, the gamma-radiation radiation sterilization promptly gets product.
Claims (4)
1, a kind of eye-surface biological film is characterized in that: for having the animal membrane to the similar curved surface of eyeball.
2, a kind of eye-surface biological film as claimed in claim 1 is characterized in that: be provided with the medicament slow release layer in the described biomembrane curved surface.
3, a kind of eye-surface biological film as claimed in claim 1 is characterized in that: be provided with in the described biomembrane curved surface through reasonable drawing and setting and make suitable expansion of fenestra and the ventilative micropore of formation.
4, a kind of eye-surface biological film as claimed in claim 1 is characterized in that: in the described biomembrane curved surface lubricating layer is set.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2007200596890U CN201161003Y (en) | 2007-11-16 | 2007-11-16 | Ocular surface biomembrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2007200596890U CN201161003Y (en) | 2007-11-16 | 2007-11-16 | Ocular surface biomembrane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201161003Y true CN201161003Y (en) | 2008-12-10 |
Family
ID=40181948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2007200596890U Expired - Lifetime CN201161003Y (en) | 2007-11-16 | 2007-11-16 | Ocular surface biomembrane |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201161003Y (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107072653A (en) * | 2014-07-23 | 2017-08-18 | 波士顿科学国际有限公司 | Apparatus and method for fixing animal tissue |
| US10443107B2 (en) | 2015-09-03 | 2019-10-15 | Boston Scientific Scimed, Inc. | Tissue modification devices, systems, and methods |
-
2007
- 2007-11-16 CN CNU2007200596890U patent/CN201161003Y/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107072653A (en) * | 2014-07-23 | 2017-08-18 | 波士顿科学国际有限公司 | Apparatus and method for fixing animal tissue |
| US10443107B2 (en) | 2015-09-03 | 2019-10-15 | Boston Scientific Scimed, Inc. | Tissue modification devices, systems, and methods |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101172166B (en) | Ocular surface biomembrane and preparation method thereof | |
| JP6889118B2 (en) | Manufacture of high-purity collagen particles and their use | |
| CN1243573C (en) | Prefabricated corneal tissue lens and its preparation method (II) | |
| CN102580153B (en) | Method for preparing allograft acellular dermal matrixes | |
| CN110478519A (en) | One kind is for soft tissue surface of a wound scar repair hydrogel dressing and preparation method thereof | |
| CN104055795B (en) | A kind of injectable implant and preparation method thereof | |
| CN103520058A (en) | Silkworm chrysalis active polypeptide after-sun repairing gel and preparation method thereof | |
| CN104523547A (en) | Preparation process research of andrias davidianus blanchard facial mask and application method of andrias davidianus blanchard facial mask | |
| CN111234007A (en) | Collagen active peptide for promoting wound healing | |
| CN102225218A (en) | A method for preparing decellularized dermal matrix using ultrasound | |
| JP2019529015A (en) | Dermal layer for transplantation with increased survival rate and method for producing the same | |
| CN109400700A (en) | A kind of preparation method of the collagen oligopeptide easily absorbed | |
| CN201161003Y (en) | Ocular surface biomembrane | |
| RU2438713C2 (en) | Biological wound covering and method of its production | |
| CN104474573A (en) | Biological mask and preparation method thereof | |
| CN101874903B (en) | Method for preparing collagen artificial skin | |
| CN105268022B (en) | A kind of preparation method of xenogenesis cell-less corium ground substance | |
| CN105833353A (en) | Preparation and application of bioengineering decellularized dermal matrix | |
| CN105688210A (en) | Yolk biological protein skin repair dressing and preparation method thereof | |
| WO2023039833A1 (en) | Use of collagen particles to promote hair follicle formation or angiogenesis | |
| CN108210159B (en) | Eye surface treatment device and preparation method thereof | |
| CN105662998A (en) | Yak hide collagen mask with ultraviolet ray resistance and preparation method | |
| TWI791290B (en) | Use of collagen particles in hair follicles formation or angiogenesis | |
| CN111888526A (en) | Skin sheet for mixed transplantation of heterogeneous species | |
| Sonawane et al. | Revolutionizing Burn Care: The Therapeutic Potential of Nile Tilapia Skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: GUANGDONG GUAN HAO BIOLOGICAL SCIENCE + TECHNOLOGY Free format text: FORMER NAME: GUANHAO BIOLOGICAL SCIENCE + TECH CO., LTD., GUANGDONG PROV. |
|
| CP03 | Change of name, title or address |
Address after: Room 408, D international business incubator, Guangzhou Science City, Guangdong, Guangzhou Province, 510663, postcode: Patentee after: Guangdong summit life sciences Co., Ltd. Address before: Room 408, D international business incubator, Guangzhou Science City, Guangdong, Guangzhou Province, 510665, postcode: Patentee before: Guanhao Biological Science & Tech Co., Ltd., Guangdong Prov. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20081210 |